辉瑞液明珠联合托吡卡胺治疗假性近视的临床疗效观察

Clinical efficacy of Pfizer Lutein combining with Tropicamide in treatment of pseudomyopia

目的探讨辉瑞液明珠联合托吡卡胺治疗假性近视的科学性及临床应用效果。方法124眼假性近视眼随机分为两组:A组为辉瑞液明珠联合0.5%托吡卡胺治疗组;B组为单用0.5%托吡卡胺治疗组。治疗30d后比较两组视力及视疲劳症状恢复情况,应用χ2检验分析两组疗效差异。所有统计数据在SPSS11.0软件包中处理。结果A组治愈45眼,有效12眼,有效率为91.93%;B组治愈22眼,有效10眼,有效率为51.61%。根据χ2检验,A组优于B组(P<0.05,χ2=5.68)。结论辉瑞液明珠联合0.5%托吡卡胺治疗组其疗效明显优于单纯应用0.5%托吡卡胺治疗组,其疗效可靠,且在服药期间均未出现任何不良反应,故此法可作为防止假性近视发展成为真性近视的预防性用药。

Objective To explore the scientificity and clinical efficacy of Pfizer Lutein combining with Tropicamide in treatment of pseudomyopia. Methods 124 pseudomyopia eyes were divided into two groups ： A group was given Pfizer Lutein combining with Tropicamide; B group was given 0. 5% Tropocamide only. 30 days after treatment, recoverence of vision and asthenopia symptom were compared between the two groups and the curative effect differences were analysed by X2 examination. All the statistical data were dealed with SPSS 11.0 software package. Results In A group, 45 eyes were cured, 12 were effective and the effective rate was 91.93%. In B group, the data were 22,10 and 51.61% respectively. According to thex2 examination, A group surpassed B group （ P 〈 0. 05 ,X2 = 5.68 ）. Conclusion The curative effect of Pfizer Lutein combining with Trepicamide is clearly better than that of single use of 0. 5% Trepocamide, with reliable efficacy and no any untoward effect during taking medicine period. Therefore, Pfizer Lutein combining with Tropicamide can be used to prevent pseudomyopia from developing into true myopia.